A Phase 2 interventional study of Naproxen Sodium (Aleve, BAY117031) and Acetaminophen ER in Osteoarthritis, Knee, sponsored by Bayer. Completed at 5 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-06-19.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing acetaminophen in Osteoarthritis, Knee — none open to participants now, none under way, none of them phase 3. Acetaminophen · Osteoarthritis, Knee.
Among the 11 studies testing acetaminophen in Osteoarthritis, Knee, this one is the 9th largest by enrollment, is the only one that started in 2018, is the only one in phase 2, and was the 9th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →None of the 11 studies testing acetaminophen in Osteoarthritis, Knee is open now. The open studies under Osteoarthritis, Knee, anywhere →
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 7 · Phase 4 1
First in 1999; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 300 across the 11 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 8 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
Bayer has 2 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing acetaminophen in Osteoarthritis, Knee, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Osteoarthritis is a common, chronic, progressive, skeletal, degenerative disorder that frequently affects several joints such as knee, hip, spine and hands.This placebo-controlled clinical trial assessed the effects of naproxen sodium, acetaminophen and celecoxib on stiffness in subjects with osteoarthritis.
The primary objective of the study was to assess the responsiveness of the Brief Arthritis Stiffness Scale (BASS) for detecting treatment effects of common over-the-counter (OTC) analgesics and a common prescription analgesic in subjects with knee osteoarthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by placebo for 4 days; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetaminophen ER · Drug: Celecoxib · Drug: Placebo
Participants received acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by placebo for 4 days; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetaminophen ER · Drug: Celecoxib · Drug: Placebo
Participants received celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by placebo for 4 days. Treatment periods were separated by a washout period of 3 to 7 days.
Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetaminophen ER · Drug: Celecoxib · Drug: Placebo
Participants received placebo for 4 days; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days
Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetaminophen ER · Drug: Celecoxib · Drug: Placebo
660 mg daily for 3 days, 440 mg on the fourth day, over-encapsulated tablet, oral (Treatment A)
3900 mg daily for 3 days, 1300 mg on the fourth day, over-encapsulated extended release (ER) tablet, oral (Treatment B)
200 mg daily for 3 days, 100 mg on the fourth day, over-encapsulated capsule, oral (Treatment C)
Over-encapsulation capsule, 4 days, oral (Treatment D)
Sum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period
Brief Arthritis Stiffness Scale (BASS) is a patient-reported outcome (PRO) instrument measuring of the severity of osteoarthritis-related stiffness in the target knee joint. The BASS score ranges from 0 to 40 and a higher score indicates worse stiffness. This endpoint was calculated by summing the changes from baseline (CFB) in BASS scores at Days 2, 3, and 4 of the treatment periods.
Time frame: 4 days
Absolute Brief Arthritis Stiffness Scale (BASS) Score at Each Time Point
Brief Arthritis Stiffness Scale (BASS) is a patient-reported outcome (PRO) instrument measuring of the severity of osteoarthritis-related stiffness in the target knee joint. The BASS score ranges from 0 to 40 and a higher score indicates worse stiffness.
Time frame: 4 days
Change From Baseline in Brief Arthritis Stiffness Scale (BASS) Score at Day 4
Brief Arthritis Stiffness Scale (BASS) is a patient-reported outcome (PRO) instrument measuring of the severity of osteoarthritis-related stiffness in the target knee joint. The BASS score ranges from 0 to 40 and a higher score indicates worse stiffness.
Time frame: Day 4
Study was conducted at multiple centers in the US between 29 June 2018 (first participant first visit) and 14 June 2019 (last participant last visit).
| Milestone | Treatment A-D-C-B | Treatment B-C-D-A | Treatment C-A-B-D | Treatment D-B-A-C |
|---|---|---|---|---|
| Started | 10 | 10 | 11 | 10 |
| Completed | 10 | 10 | 10 | 9 |
| Not completed | 0 | 0 | 1 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
Brief Arthritis Stiffness Scale (BASS) is a patient-reported outcome (PRO) instrument measuring of the severity of osteoarthritis-related stiffness in the target knee joint. The BASS score ranges from 0 to 40 and a higher score indicates worse stiffness. This endpoint was calculated by summing the changes from baseline (CFB) in BASS scores at Days 2, 3, and 4 of the treatment periods.
| Scores on a scale | Naproxen | Acetaminophen ER | Celecoxib | Placebo |
|---|---|---|---|---|
| Sum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period | -12.6 ± 5.46 | -13.6 ± 5.46 | -11.7 ± 5.46 | -2.3 ± 5.47 |
Brief Arthritis Stiffness Scale (BASS) is a patient-reported outcome (PRO) instrument measuring of the severity of osteoarthritis-related stiffness in the target knee joint. The BASS score ranges from 0 to 40 and a higher score indicates worse stiffness.
| Scores on a scale | Naproxen | Acetaminophen ER | Celecoxib | Placebo |
|---|---|---|---|---|
| Day 1 | 23.0 ± 1.84 | 23.3 ± 1.84 | 24.6 ± 1.84 | 22.6 ± 1.85 |
| Day 2 | 20.8 ± 1.62 | 19.7 ± 1.62 | 20.6 ± 1.62 | 23.2 ± 1.62 |
| Day 3 | 18.4 ± 1.97 | 18.4 ± 1.97 | 18.9 ± 1.98 | 22.4 ± 1.98 |
| Day 4 | 18.1 ± 1.97 | 18.0 ± 1.97 | 18.5 ± 1.97 | 22.0 ± 1.97 |
Brief Arthritis Stiffness Scale (BASS) is a patient-reported outcome (PRO) instrument measuring of the severity of osteoarthritis-related stiffness in the target knee joint. The BASS score ranges from 0 to 40 and a higher score indicates worse stiffness.
| Scores on a scale | Naproxen | Acetaminophen ER | Celecoxib | Placebo |
|---|---|---|---|---|
| Change From Baseline in Brief Arthritis Stiffness Scale (BASS) Score at Day 4 | -5.2 ± 1.97 | -5.3 ± 1.97 | -4.8 ± 1.97 | -1.3 ± 1.97 |
Collected over After the first dose of the investigational medicinal product (IMP) until the end of the treatment phase, up to 37 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naproxen | 0/39 (0%) | 0/39 (0%) | 5/39 (12.8%) |
| Acetaminophen ER | 0/40 (0%) | 0/40 (0%) | 8/40 (20%) |
| Celecoxib | 0/40 (0%) | 0/40 (0%) | 10/40 (25%) |
| Placebo | 0/39 (0%) | 0/39 (0%) | 3/39 (7.7%) |
| Event | Naproxen | Acetaminophen ER | Celecoxib | Placebo |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 0/39 | 2/40 | 0/40 | 0/39 |
| Abdominal distensionGastrointestinal disorders | 1/39 | 0/40 | 0/40 | 0/39 |
| Abdominal painGastrointestinal disorders | 1/39 | 0/40 | 0/40 | 0/39 |
| DiarrhoeaGastrointestinal disorders | 0/39 | 0/40 | 0/40 | 1/39 |
| Dry mouthGastrointestinal disorders | 1/39 | 0/40 | 0/40 | 0/39 |
| Faeces discolouredGastrointestinal disorders | 1/39 | 0/40 | 0/40 | 0/39 |
| Upper respiratory tract infectionInfections and infestations | 0/39 | 0/40 | 1/40 | 1/39 |
| Joint injuryInjury, poisoning and procedural complications | 1/39 | 0/40 | 0/40 | 0/39 |
| Heart rate decreasedInvestigations | 1/39 | 0/40 | 0/40 | 0/39 |
| HeadacheNervous system disorders | 1/39 | 1/40 | 1/40 | 1/39 |
Safety population: all participants who received at least one dose of investigational medicinal product (IMP).
| Age, Continuous(Years) | Treatment A-D-C-B | Treatment B-C-D-A | Treatment C-A-B-D | Treatment D-B-A-C | Total |
|---|---|---|---|---|---|
| Mean | 62.4 ± 9.20 | 61.3 ± 8.77 | 61.6 ± 7.55 | 59.6 ± 8.28 | 61.2 ± 8.19 |
| Sex: Female, Male(Participants) | Treatment A-D-C-B | Treatment B-C-D-A | Treatment C-A-B-D | Treatment D-B-A-C | Total |
|---|---|---|---|---|---|
| Female | 9 | 6 | 11 | 7 | 33 |
| Male | 1 | 4 | 0 | 3 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Treatment A-D-C-B | Treatment B-C-D-A | Treatment C-A-B-D | Treatment D-B-A-C | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 2 | 1 | 4 |
| Not Hispanic or Latino | 9 | 10 | 9 | 9 | 37 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment A-D-C-B | Treatment B-C-D-A | Treatment C-A-B-D | Treatment D-B-A-C | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 5 | 2 | 5 | 16 |
| White | 6 | 5 | 8 | 5 | 24 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Brief Arthritis Stiffness Scale (BASS)(Scores on a scale) | Treatment A-D-C-B | Treatment B-C-D-A | Treatment C-A-B-D | Treatment D-B-A-C | Total |
|---|---|---|---|---|---|
| Treatment period 1 | 26.7 ± 4.90 | 25.8 ± 5.05 | 27.8 ± 5.56 | 23.1 ± 5.35 | 26.0 ± 5.31 |
| Treatment period 2 | 25.8 ± 7.74 | 21.8 ± 8.32 | 22.3 ± 9.74 | 25.3 ± 4.64 | 23.8 ± 7.74 |
| Treatment period 3 | 26.3 ± 5.56 | 17.7 ± 10.03 | 22.9 ± 10.29 | 24.0 ± 6.48 | 22.7 ± 8.69 |
| Treatment period 4 | 21.9 ± 10.56 | 20.3 ± 6.40 | 24.2 ± 9.95 | 23.8 ± 7.92 | 22.5 ± 8.68 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Ran from Jun 2018 to primary completion in Jun 2019, 11 months.
Results were first posted in Jun 2020, 1 year after primary completion.
Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's 11 months is below that.
Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Naproxen · Acetaminophen · Celecoxib